 "Natco Pharma gains on USFDA nod for generic Glycopyrrolate tablets")
Natco Pharma was trading higher by 4% to Rs 552, extending its Wednesday’s 6% rally on the BSE, after the company announced that it has received US Food and Drug Administration (FDA) for generic version of Glycopyrrolate tablets.
“We received from our US agent on 22nd June 2016 intimating the approval for generic version of Glycopyrrolate Tablets 1mg and 2mg from US FDA (Reference Listed Drug (RLD) is Robinul Tablets, 1 mg and Robinul Forte Tablets, 2 mg, of Casper Pharma LLC),” Natco Pharma said in a statement.
Glycopyrrolate will be manufactured at the company’s finished dosage facility located at Kothur, near Hyderabad.
Natco Pharma said, the market potential of the product is not significant.
The company believes the product will not have any material or financial impact on its operations, it added.
The stock hit a high of Rs 572 on the BSE in intra-day trade. The trading volumes on the counter jumped more than three-fold with a combined 1.86 million shares changed hands on the BSE and NSE till 01:32 PM.
“We received from our US agent on 22nd June 2016 intimating the approval for generic version of Glycopyrrolate Tablets 1mg and 2mg from US FDA (Reference Listed Drug (RLD) is Robinul Tablets, 1 mg and Robinul Forte Tablets, 2 mg, of Casper Pharma LLC),” Natco Pharma said in a statement.
Glycopyrrolate will be manufactured at the company’s finished dosage facility located at Kothur, near Hyderabad.
Natco Pharma said, the market potential of the product is not significant.
The company believes the product will not have any material or financial impact on its operations, it added.
The stock hit a high of Rs 572 on the BSE in intra-day trade. The trading volumes on the counter jumped more than three-fold with a combined 1.86 million shares changed hands on the BSE and NSE till 01:32 PM.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%